A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases and Improves Cancer Immunity in Preclinical Lung Cancer Models
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2548
Full Text
Open PDFAbstract
Available in full text
Date
February 22, 2019
Authors
Publisher
American Association for Cancer Research (AACR)